Paolo Caimi
Case Western Reserve University
H-index: 38
North America-United States
Top articles of Paolo Caimi
Siltuximab Prophylaxis Prior to Standard of Care CD19 Directed Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: Interim Results from a Phase I Clinical Trial
Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
2024/2/1
Ying Huang
H-Index: 10
Paolo Caimi
H-Index: 20
Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities–a Multicenter Retrospective Analysis
Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
2024/2/1
Outcomes in Patients (pts) with R/R Large B-Cell Lymphoma (LBCL) Who Received Nonconforming Product (NCP) to Commercial Release of Lisocabtagene Maraleucel (liso-cel) in the …
Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
2024/2/1
In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
Ejhaem
2024/2
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial
Blood advances
2024/1/9
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial
Clinical cancer research
2024/1/5
A multicenter study of posttransplant low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
Blood Advances
2024/1/5
Consensus recommendations on the management of toxicity associated with CD3× CD20 bispecific antibody therapy
Blood
2024/4/18
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study
Haematologica
2024/4/4
Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models
Cancer Immunology Research
2024/4/2
BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell …
American journal of hematology
2024/3/25
Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma
Leukemia & Lymphoma
2024/3/8
Yanwen Chen
H-Index: 8
Paolo Caimi
H-Index: 20
Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma …
Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
2024/2/1
Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel
Bone Marrow Transplantation
2023/5
Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy
Blood
2023/11/28
Abstract CT125: A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in …
Cancer Research
2023/4/14
Prescription Patterns of Initial Therapy and Outcomes of Elderly Hodgkin Lymphoma Patients. Toxicity and Efficacy Balance of Attenuated Initial Therapy
Blood
2023/11/28
Ibrutinib is associated with increased cardiovascular events and major bleeding in older CLL patients
Cardio Oncology
2023/4/1
Long Vu
H-Index: 13
Paolo Caimi
H-Index: 20
Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment
Blood
2023/11/28
Development and Clinical Validation of an Ultra-Fast CAR-T Manufacturing Platform Enabling Production of CAR-T Cells in Less Than 1 Day
Blood
2023/11/28
Paolo Caimi
H-Index: 20
James Martin
H-Index: 13
Co-Authors
